Summary of Significant Accounting Policies - Revenue Recognition (Details)		1 Months Ended		6 Months Ended	12 Months Ended
	Apr. 15, 2020 USD ($)	Oct. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) contract item	Dec. 31, 2020 USD ($)	Aug. 28, 2018 shares
Disaggregation of Product Revenue
Practical Expedients, not disclose the value of unsatisfied performance obligations					true
Warrants to purchase (in shares) | shares							9,580
Number of contracts | contract					2
Number of specialty pharmacies. | item					2
Number of portfolio of contract | contract					1
Maximum
Disaggregation of Product Revenue
Product revenue				$ 22,000,000.0
Fee Settlement Agreement
Disaggregation of Product Revenue
Trial delay fee event of failure of initiation of phase 2 study		$ 2,500,000
Shares issued (in shares) | shares		2,000,000
Warrants to purchase (in shares) | shares		6,218,954
Exercise price (in dollars per share) | $ / shares		$ 0.0001
Settlement loss		$ 1,000,000.0
Atlas
Disaggregation of Product Revenue
Trial delay fee event of failure of initiation of phase 2 study			$ 2,500,000
Deferred revenue recorded derecognized					$ 1,500,000
Total transaction price					0
Atlas | Patent purchase agreement
Disaggregation of Product Revenue
Upfront cash payments received	$ 1,500,000
Mytesi
Disaggregation of Product Revenue
Product revenue					3,300,000	$ 9,300,000
Mytesi | Specialty Pharmacies
Disaggregation of Product Revenue
Product revenue					993,000	0
Neonorm
Disaggregation of Product Revenue
Product revenue					$ 62,000	$ 76,000
License | Atlas | License Agreement
Disaggregation of Product Revenue
License term	10 years
Obligated initiate proof of concept	9 months